1Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42: 157-163.
2Kim YH, Kim JS, Choi YH, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. Int J Clin Oncol, 2002, 7(2): 114-119.
3Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer[J]. Yher Clin Risk Manag, 2009, 5: 781-787.
4Cohen MH, Cortazar P, Justice R, et al. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)[J]. Oncologist, 2010, 15(12): 1352-1358.
5Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1): 122S-150S.
6孙燕,周际昌.1f缶床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:97-107.
7Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 92-98. R.
8ollins KD, Lindley C. Pemetrexed: a multitargeted antifolate[J]. Clin Ther, 2005, 27(9): 1343-1382.
9Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mnl Cancer Ther. 2007,6(2): 404-417.
10Standfield L, Weston AR, Barraclough H, et al. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence[J]. Respirology, 2011, 16(8): 1210-1220.
2Georgescu C, Margaritescu C, Osman I, et al. Therapeutic management of massive subcutaneous emphysema, bilateral pneumothorax and pneumomediastinum after anterior cordectomy for in situ vocal cord carcinoma-case report [J]. Chirurgia (Bucur), 2014, 109(6) : 822-826.
4Aahonen LM, Rautiainen N, Sellman J, et al. Voice quality after treatment of early vocal cord cancer:a random ized trial comparing laser surgery with radiation therapy [J].Int J Radiat Oncol Biol Phys,2014,90(2):255- 260.
